Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hum Pathol ; 144: 34-39, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38224873

RESUMO

The majority of melanocytic proliferations can be readily categorized as benign or malignant based on histologic assessment under the microscope by a trained dermatopathologist. However, a subset of lesions, termed Atypical Melanocytic Proliferations (AMPs), are histologically ambiguous, leading to possible diagnostic error and suboptimal treatment. Mutations in the promoter region of the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), are commonly found in melanomas but are rare in melanocytic nevi. In this study, we aimed to determine the prevalence of hot spot TERT promoter (TERT-p) mutations in AMPs with adverse melanoma-specific outcome. Studies were approved by respective institutional review boards. Using a multi-center database, we identified seven cases of melanocytic proliferations with a clinical follow-up period of at least 4 years, which were initially diagnosed as AMPs, and which recurred either as melanoma at site of prior biopsy or as metastatic melanoma. Sequencing of the TERT-p region showed hotspot mutations in three cases (43 %), suggesting that TERT-p mutations are enriched and could aid in the identification of AMPs with adverse outcome. In comparison with existing ancillary techniques for prognostication of AMPs, TERT-p mutation analysis may have advantages in terms of cost effectiveness and turnaround time, and is a promising diagnostic parameter with potential widespread utility.


Assuntos
Melanoma , Nevo Pigmentado , Neoplasias Cutâneas , Telomerase , Humanos , Melanoma/patologia , Neoplasias Cutâneas/patologia , Recidiva Local de Neoplasia , Nevo Pigmentado/diagnóstico , Mutação , Telomerase/genética
2.
Skin Therapy Lett ; 25(5): 7-11, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33196157

RESUMO

Nicotinamide (or niacinamide), a form of vitamin B3 that is often confused with its precursor nicotinic acid (or niacin), is a low-cost, evidence-based oral treatment option for actinic keratosis, squamous cell carcinomas, basal cell carcinomas, and bullous pemphigoid. Despite its favorable safety profile and affordability, the integration of nicotinamide into clinical practice is an ongoing process, and like many over-the-counter supplements it has faced some barriers. The purpose of this article is to address some of those barriers by reviewing its efficacy, safety profile, and emphasizing the difference between nicotinamide and niacin. Lastly, we offer practical guidance around recommendations and the availability of nicotinamide, which can be hard to find for patients and providers alike.


Assuntos
Niacinamida/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Complexo Vitamínico B/uso terapêutico , Administração Oral , Suplementos Nutricionais , Humanos , Niacinamida/administração & dosagem , Niacinamida/efeitos adversos , Complexo Vitamínico B/administração & dosagem , Complexo Vitamínico B/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...